Regulatory Hurdles for Increased Availability of Cannabis-Infused Edibles

Published

 

Merril Gilbert, founder and CEO of TraceTrust: One is getting it declassified as a Schedule I narcotic. It’s clearly not that. There is no addictive qualities: it’s a combination of other things. But it’s also, again, how do I counteract it and not knowing how it’s going to react for different people. You’re going to have the same reaction as if you have a peanut allergy and we have to be really conscious of that. So, again, creating a standard like we’re doing in this same manner and together with other types of certifications –nonGMO and vegan– and really aligning together, raising up together and not competing against each other is crucial now.

0 Comments

For editorial opportunities:

Jennifer Barrett, Senior Editor
jbarrett@mjhlifesciences.com

Gabrielle Ientile, Assistant Editor
gientile@mjhlifesciences.com

For advertising opportunities:

William Mulderry, VP, Group Publisher
wmulderry@mjhlifesciences.com

Eric Temple-Morris, VP, Healthcare
etemple-morris@mmhgroup.com

William Culberson, National Accounts Manager
wculberson@mjhlifesciences.com

Lauren Ruperto, National Accounts Manager
lruperto@mjhlifesciences.com

Powered by Medstro